We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Trump’s FDA pick, Marty Makary, appears to be quelling fears about a major disruption to biotech and pharma. Neuralink ...

Eton Pharmaceuticals has acquired the US rights to Amglidia, a treatment developed for neonatal diabetes mellitus, from France-based biotechnology company AMMTeK. Amglidia, also known as glibenclamide ...

Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

To support patients, BridgeBio will provide Attruby free for life to U.S. clinical trial participants. The company has also ...

Don't Miss our Black Friday Offers: Mani Foroohar has given his Buy rating due to a combination of factors including the recent FDA approval of BridgeBio Pharma’s drug Attruby for treating ...

Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...